Papalocal
Loading…
News
← All news
Health

Urine test detects 9 in 10 bladder cancers in NHS trial, could cut cystoscopies by nearly three-quarters

A genetic urine assay tested across seven NHS hospitals correctly identified 71 of 77 bladder cancers — including every muscle-invasive case — and could eliminate roughly 730 invasive procedures per 1,000 patients investigated.

How does this story make you feel?

A urine test that scans DNA for mutations across 23 bladder-cancer-linked genes has correctly identified more than nine in ten bladder cancers in a real-world NHS trial — and a negative result was reliable enough to rule out the disease in more than 99 percent of cases. The findings, published in European Urology Oncology, raise the prospect of thousands of patients avoiding the invasive camera procedure that currently sits at the centre of bladder cancer diagnosis.

The study enrolled 964 patients referred to hematuria clinics across seven NHS hospitals between October 2024 and June 2025. All had blood in their urine — the most common warning sign of bladder cancer — and all underwent both standard cystoscopy and the experimental GALEAS Bladder test, developed by Nonacus Clinical Services and the University of Birmingham. Of the 77 patients ultimately confirmed to have bladder cancer, the urine test detected 71, a sensitivity of 92 percent.

Critically, GALEAS caught every one of the 17 muscle-invasive bladder cancers — the most aggressive form of the disease — and 35 of 36 high-grade tumours. Of the six cases it missed, four involved tumours at a very early stage. The test also identified 30 percent of patients who had non-visible haematuria.

This prospective study shows that the very promising early performance has now been reproduced across multiple NHS centres and in a large real-world patient population.— Professor Richard Bryan, Director, University of Birmingham's Bladder Cancer Research Centre and study co-author
These results show that molecular urine testing can be used now to help clinicians decide which patients need an urgent cystoscopy and which can safely have that procedure deferred.— Professor Richard Bryan, Director, University of Birmingham's Bladder Cancer Research Centre and study co-author

The numbers make the potential scale of change concrete. Modelling drawn from the study data led the research team to project that the assay could spare roughly 730 patients per 1,000 haematuria referrals from urgent cystoscopies, while still catching the great majority of cancers. That matters because, while hematuria is present in more than 90 percent of bladder cancer patients, only 8 to 19 percent of haematuria referrals ever result in a positive diagnosis — meaning the overwhelming majority of patients currently undergo an uncomfortable invasive procedure for nothing.

Cystoscopy involves inserting a thin tube fitted with a camera through the urethra to examine the bladder. It is effective but invasive, resource-intensive and uncomfortable for many patients. The current gold standard also combines urinary tract imaging and analysis of resected tissue — procedures that require specialist availability, in-person attendance, and significant NHS capacity.

GALEAS Bladder works differently: a patient provides a urine sample, which is then subjected to a multimarker genetic assay examining proteins and other traces of 23 genes associated with bladder cancer. One notable feature is that the test can be run on urine samples collected for other purposes entirely, potentially revealing early signs of bladder cancer in people not previously considered at risk.

The most important message for the patient is that they don't have to do anything to be part of this.— Andy Goffe, Lead Urology Nurse Consultant, Dorset County Hospital Foundation Trust, who leads the GALEAS Bladder service evaluation
We also explain that we're looking for ways to replace a cystoscopy, so perhaps it is not a surprise that, to date, 100% of patients have agreed to get involved.— Andy Goffe, Lead Urology Nurse Consultant, Dorset County Hospital Foundation Trust

The test is not waiting for regulatory approval to find its footing. GALEAS Bladder is already on the market for urologists to buy, with testing carried out at the company's ISO 15189-accredited laboratories. Bupa and the London Clinic are among the private health care providers that reimburse for it, and NHS trusts — including University Hospitals Leicester and University Hospitals Coventry and Warwickshire — along with health boards in Wales have taken it up.

It has been used to clear cystoscopy waiting-list backlogs that have since been eliminated.— Douglas Ward, Senior Research Fellow, University of Birmingham, and study co-author

Ward further noted that the National Institute for Health and Care Excellence (NICE) has made urinary biomarkers for bladder cancer a priority topic for HealthTech evaluation this year, and that additional NHS organisations are in the process of introducing the test. The study authors, however, cautioned that the research was observational and conducted over a limited time frame, and that longer-term follow-up would be needed to further validate the findings.

The disease the test is targeting is far from rare. The International Agency for Research on Cancer estimates that more than 635,000 people were diagnosed with bladder cancer worldwide in 2024 and more than 225,000 died from it. In the United States alone, the CDC estimates roughly 84,000 people will develop it this year, making it the sixth most common cancer in the country.

Why it matters — If validated at scale, a cheap, non-invasive urine test that reliably rules out bladder cancer could spare hundreds of thousands of patients annually from an uncomfortable invasive procedure — and help overstretched urology services focus resources on those who genuinely need urgent care.

⚠ Not yet confirmed

  • The test identified 30 percent of patients with non-visible haematuria

Reported by goodnewsnetwork.org, birmingham.ac.uk, newsweek.com, deccanherald.com, urologytimes.com

People in this story

Community

Be the first to comment.

Share this story
Text Email